{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:37:03Z","timestamp":1793655423526,"version":"4.5.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10147-025-02808-z","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:51:19Z","timestamp":1749448279000},"page":"1797-1804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Different outcomes by sex in metastatic gastrointestinal stromal tumor patients receiving imatinib: a trial-level analysis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8793-8138","authenticated-orcid":false,"given":"Antonella","family":"Venturino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-6793","authenticated-orcid":false,"given":"Giuseppe Antonio","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2808_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K Soreide","year":"2016","unstructured":"Soreide K, Sandvik OM, Soreide JA et al (2016) Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 40:39\u201346. https:\/\/doi.org\/10.1016\/j.canep.2015.10.031","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 10","key":"2808_CR2","doi-asserted-by":"publisher","first-page":"x280","DOI":"10.1093\/annonc\/mdl274","volume":"17","author":"H Joensuu","year":"2006","unstructured":"Joensuu H (2006) Gastrointestinal stromal tumor (GIST). Ann Oncol 17(Suppl 10):x280\u2013x286. https:\/\/doi.org\/10.1093\/annonc\/mdl274","journal-title":"Ann Oncol"},{"issue":"12","key":"2808_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s12094-019-02094-y","volume":"21","author":"DY Yang","year":"2019","unstructured":"Yang DY, Wang X, Yuan WJ et al (2019) Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis. Clin Transl Oncol 21(12):1654\u20131662. https:\/\/doi.org\/10.1007\/s12094-019-02094-y","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"2808_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihimaki J et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265\u2013274. https:\/\/doi.org\/10.1016\/S1470-2045(11)70299-6","journal-title":"Lancet Oncol"},{"key":"2808_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bjs.10809","volume":"105","author":"WTA van der Graaf","year":"2018","unstructured":"van der Graaf WTA, Tielen R, Bonenkamp JJ et al (2018) Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg 105:1020\u20131027. https:\/\/doi.org\/10.1002\/bjs.10809","journal-title":"Br J Surg"},{"issue":"11","key":"2808_CR6","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1245\/s10434-022-12063-5","volume":"29","author":"TL Sutton","year":"2022","unstructured":"Sutton TL, Walker BS, Billingsley KG et al (2022) Ten-year survivorship in patients with metastatic gastrointestinal stromal tumors. Ann Surg Oncol 29(11):7123\u20137132. https:\/\/doi.org\/10.1245\/s10434-022-12063-5","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2808_CR7","doi-asserted-by":"publisher","first-page":"7912","DOI":"10.1245\/s10434-021-10062-6","volume":"28","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Walker BS, Billingsley KG et al (2021) Disease-free interval is associated with oncologic outcomes in patients with recurrent gastrointestinal stromal tumor. Ann Surg Oncol 28(12):7912\u20137920. https:\/\/doi.org\/10.1245\/s10434-021-10062-6","journal-title":"Ann Surg Oncol"},{"key":"2808_CR8","doi-asserted-by":"publisher","first-page":"8293261","DOI":"10.1155\/2019\/8293261","volume":"2019","author":"Z Chen","year":"2018","unstructured":"Chen Z, Lin R-M, Bai Y-K et al (2018) Establishment and verification of prognostic nomograms for patients with gastrointestinal stromal tumors: a SEER-based study. BioMed Res Int 2019:8293261. https:\/\/doi.org\/10.1155\/2019\/8293261","journal-title":"BioMed Res Int"},{"issue":"18","key":"2808_CR9","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2002.03.095","volume":"20","author":"S Singer","year":"2002","unstructured":"Singer S, Rubin BP, Lux ML et al (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20(18):3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2002.03.095","journal-title":"J Clin Oncol"},{"issue":"1","key":"2808_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s101200300005","volume":"6","author":"Y Fujimoto","year":"2003","unstructured":"Fujimoto Y, Nakanishi Y, Yoshimura K et al (2003) Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 6(1):39\u201348. https:\/\/doi.org\/10.1007\/s101200300005","journal-title":"Gastric Cancer"},{"issue":"6","key":"2808_CR11","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.esmoop.2022.100649","volume":"7","author":"NS Ijzerman","year":"2022","unstructured":"Ijzerman NS, van Werkhoven E, Mohammadi M et al (2022) Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? ESMO Open 7(6):100649. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100649","journal-title":"ESMO Open"},{"key":"2808_CR12","unstructured":"Wells G, Shea B, O'Connell D, et al. (2021) The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2808_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127\u20131134. https:\/\/doi.org\/10.1016\/S0140-6736(04)17098-0","journal-title":"Lancet"},{"key":"2808_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejca.2015.10.069","volume":"52","author":"A Patrikidou","year":"2016","unstructured":"Patrikidou A, Domont J, Chabaud S et al (2016) Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 52:173\u2013180. https:\/\/doi.org\/10.1016\/j.ejca.2015.10.069","journal-title":"Eur J Cancer"},{"key":"2808_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626\u2013632. https:\/\/doi.org\/10.1200\/JCO.2007.13.4452","journal-title":"J Clin Oncol"},{"issue":"4","key":"2808_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/0284186X.2011.636753","volume":"51","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Ryu MH, Kim KM et al (2012) Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GOST): the Korean GIST Study Group (KGSG) study. Acta Oncol 51(4):528\u2013536. https:\/\/doi.org\/10.3109\/0284186X.2011.636753","journal-title":"Acta Oncol"},{"key":"2808_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","volume":"40","author":"S Bauer","year":"2014","unstructured":"Bauer S, Rutkowski P, Hohenberger P et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40:412\u2013419. https:\/\/doi.org\/10.1016\/j.ejso.2013.12.020","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2808_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jamcollsurg.2014.02.037","volume":"219","author":"DA Bischof","year":"2014","unstructured":"Bischof DA, Kim Y, Blazer DG III et al (2014) Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. J Am Coll Surg 219(3):439\u2013449. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.02.037","journal-title":"J Am Coll Surg"},{"issue":"8","key":"2808_CR19","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s11605-015-2845-9","volume":"19","author":"KW Brudvik","year":"2015","unstructured":"Brudvik KW, Patel SH, Roland CL et al (2015) Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg 19(8):1476\u20131483. https:\/\/doi.org\/10.1007\/s11605-015-2845-9","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"2808_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00595-016-1351-3","volume":"47","author":"S Sato","year":"2017","unstructured":"Sato S, Tsujinaka T, Masuzawa T et al (2017) Role of metastasectomy for recurrent\/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today 47(1):58\u201364. https:\/\/doi.org\/10.1007\/s00595-016-1351-3","journal-title":"Surg Today"},{"issue":"46","key":"2808_CR21","doi-asserted-by":"publisher","first-page":"e8240","DOI":"10.1097\/MD.0000000000008240","volume":"96","author":"YN Shi","year":"2017","unstructured":"Shi YN, Li Y, Wang LP et al (2017) Gastrointestinal stromal tumor (GIST) with liver metastases. An 18-year experience from the GIST cooperation group in North China. Medicine 96(46):e8240. https:\/\/doi.org\/10.1097\/MD.0000000000008240","journal-title":"Medicine"},{"issue":"10","key":"2808_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","volume":"56","author":"I Hompland","year":"2017","unstructured":"Hompland I, Bruland OS, Holmebakk T et al (2017) Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol 56(10):1317\u20131323. https:\/\/doi.org\/10.1080\/0284186X.2017.1330555","journal-title":"Acta Oncol"},{"key":"2808_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejca.2017.09.025","volume":"86","author":"MC Verboom","year":"2017","unstructured":"Verboom MC, Kloth JSL, Swen JJ et al (2017) Genetic polymorphysms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. Eur J Cancer 86:226\u2013232. https:\/\/doi.org\/10.1016\/j.ejca.2017.09.025","journal-title":"Eur J Cancer"},{"key":"2808_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000484102","volume":"97","author":"K Ogata","year":"2018","unstructured":"Ogata K, Kimura A, Nakazawa N et al (2018) Long-term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors. Digestion 97:20\u201325. https:\/\/doi.org\/10.1159\/000484102","journal-title":"Digestion"},{"key":"2808_CR25","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cam4.1994","volume":"8","author":"JH Kim","year":"2019","unstructured":"Kim JH, Ryu MH, Yoo C et al (2019) Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: a 14-year, single-center experience. Cancer Med 8:1034\u20131043. https:\/\/doi.org\/10.1002\/cam4.1994","journal-title":"Cancer Med"},{"key":"2808_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1073274819863776","volume":"26","author":"KD Hung","year":"2019","unstructured":"Hung KD, Van QL, Hoang GN et al (2019) Imatinib mesylate for patients with unresectable or recurrent gastrointestinal stromal tumors: 10-year experience from Vietnam. Cancer Control 26:1\u20137. https:\/\/doi.org\/10.1177\/1073274819863776","journal-title":"Cancer Control"},{"issue":"8","key":"2808_CR27","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1245\/s10434-020-08244-9","volume":"27","author":"X Zhang","year":"2020","unstructured":"Zhang X, Ning L, Hu Y et al (2020) Prognostic factors for primary localized gastrointestinal stromal tumors after radical resection: Sandong gastrointestinal surgery study group. Ann Surg Oncol 27(8):2812\u20132821. https:\/\/doi.org\/10.1245\/s10434-020-08244-9","journal-title":"Ann Surg Oncol"},{"key":"2808_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/834136","volume":"2014","author":"M Lv","year":"2014","unstructured":"Lv M, Wu C, Zheng Y et al (2014) Incidence and survival analysis of gastrointestinal stromal tumors in Shangai: a population-based study from 2001 to 2010. Gastroenterol Res Pract 2014:834136. https:\/\/doi.org\/10.1155\/2014\/834136","journal-title":"Gastroenterol Res Pract"},{"issue":"7","key":"2808_CR29","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-007-9377-9","volume":"14","author":"P Rutkowski","year":"2007","unstructured":"Rutkowski P, Nowecki ZI, Michej W et al (2007) Risk criteria and prognostic gactors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14(7):2018\u20132027. https:\/\/doi.org\/10.1245\/s10434-007-9377-9","journal-title":"Ann Surg Oncol"},{"key":"2808_CR30","doi-asserted-by":"publisher","first-page":"922378","DOI":"10.12659\/MSM.922378","volume":"26","author":"M Liu","year":"2020","unstructured":"Liu M, Song C, Zhang P et al (2020) A nomogram for predicting cancer-specific survival of patients with gastrointestinal stromal tumors. Med Sci Monit 26:922378. https:\/\/doi.org\/10.12659\/MSM.922378","journal-title":"Med Sci Monit"},{"issue":"10","key":"2808_CR31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.ejso.2018.07.004","volume":"44","author":"W Song","year":"2018","unstructured":"Song W, Lv CG, Miao DL et al (2018) Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours. Eur J Surg Oncol 44(10):1657\u20131665. https:\/\/doi.org\/10.1016\/j.ejso.2018.07.004","journal-title":"Eur J Surg Oncol"},{"key":"2808_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13293-020-00321-8","volume":"11","author":"J Rong","year":"2020","unstructured":"Rong J, Chen S, Song C et al (2020) The prognostic value of gender in gastric gastrointestinal stromal tumors: a propensity score matching analysis. Biol Sex Differ 11:43. https:\/\/doi.org\/10.1186\/s13293-020-00321-8","journal-title":"Biol Sex Differ"},{"issue":"10","key":"2808_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/01.pas.0000172190.79552.8b","volume":"29","author":"M Miettinen","year":"2005","unstructured":"Miettinen M, Lasota J, Sobin LH (2005) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29(10):1373\u20131381. https:\/\/doi.org\/10.1097\/01.pas.0000172190.79552.8b","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2808_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/j.gastro.2023.11.284","volume":"166","author":"M Sun","year":"2024","unstructured":"Sun M, Tong Y, Yuan W et al (2024) Proteomic characterization identifies clinically relevant subgroups of gastrointestinal stromal tumors. Gastroenterol 166(3):450\u2013465. https:\/\/doi.org\/10.1053\/j.gastro.2023.11.284","journal-title":"Gastroenterol"},{"issue":"19","key":"2808_CR35","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1158\/1078-0432.CCR-21-1221","volume":"27","author":"AK Sharma","year":"2021","unstructured":"Sharma AK, de la Torre J, Ijzerman NS et al (2021) Location of gastrointestinal stromal tumor (GIST) in the stomach predicts tumor mutation profile and drug sensitivity. Clin Cancer Res 27(19):5334\u20135342","journal-title":"Clin Cancer Res"},{"key":"2808_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2020.05.025","volume":"136","author":"NS IJzerman","year":"2020","unstructured":"IJzerman NS, Groenland SL, Koenen AM et al (2020) Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours\u2014Results from daily clinical prectice. Eur J Cancer 136:140\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2020.05.025","journal-title":"Eur J Cancer"},{"issue":"1","key":"2808_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C et al (2006) Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62(1):97\u2013112. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02719.x","journal-title":"Br J Clin Pharmacol"},{"issue":"24","key":"2808_CR38","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1158\/1078-0432","volume":"27","author":"SL Groenland","year":"2021","unstructured":"Groenland SL, Verheijen RB, Joerger M et al (2021) Precision dosing of targeted therapies is ready for prime time. Clin Cancer Res 27(24):6644\u20136652. https:\/\/doi.org\/10.1158\/1078-0432","journal-title":"Clin Cancer Res"},{"issue":"7\u20138","key":"2808_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000487511","volume":"41","author":"P Reichardt","year":"2018","unstructured":"Reichardt P (2018) The story of imatinib in GIST\u2014a journey through the development of a targeted therapy. Oncol Res Treat 41(7\u20138):472\u2013477. https:\/\/doi.org\/10.1159\/000487511","journal-title":"Oncol Res Treat"},{"issue":"59","key":"2808_CR40","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.18632\/oncotarget.27277","volume":"10","author":"C Serrano","year":"2019","unstructured":"Serrano C, Fletcher JA (2019) Overcoming heterogeneity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget 10(59):6286\u20136287. https:\/\/doi.org\/10.18632\/oncotarget.27277","journal-title":"Oncotarget"},{"issue":"3","key":"2808_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/jgo.2016.09.15","volume":"8","author":"PJ Oppelt","year":"2017","unstructured":"Oppelt PJ, Hirbe AC, Van Tine BA (2017) Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol 8(3):466\u2013473. https:\/\/doi.org\/10.21037\/jgo.2016.09.15","journal-title":"J Gastrointest Oncol"},{"issue":"34","key":"2808_CR42","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY et al (2022) Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol 40(34):3918\u20133928. https:\/\/doi.org\/10.1200\/JCO.22.00294","journal-title":"J Clin Oncol"},{"key":"2808_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108475","volume":"248","author":"A Di Vito","year":"2023","unstructured":"Di Vito A, Ravegnini G, Gorini F et al (2023) The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): a lesson from ripretinib. Pharmacol Ther 248:108475. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108475","journal-title":"Pharmacol Ther"},{"key":"2808_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10120-016-0672-7","volume":"20","author":"L Consolino","year":"2017","unstructured":"Consolino L, Long DL, Sciortino M et al (2017) Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging. Gastric Cancer 20:629\u2013639. https:\/\/doi.org\/10.1007\/s10120-016-0672-7","journal-title":"Gastric Cancer"},{"issue":"6","key":"2808_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/0300891618765543","volume":"104","author":"P Rutkowski","year":"2018","unstructured":"Rutkowski P, Teterycz P, Klimczak A et al (2018) Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib. Tumori 104(6):415\u2013422. https:\/\/doi.org\/10.1177\/0300891618765543","journal-title":"Tumori"},{"key":"2808_CR46","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/bjc.2015.70","volume":"112","author":"PY OuYang","year":"2015","unstructured":"OuYang PY, Zhang LN, Lan XW et al (2015) The significant survival advantage of female sex in nasopharingeal carcinoma: a propensity-matched analysis. Br J Cancer 112:1554\u20131561. https:\/\/doi.org\/10.1038\/bjc.2015.70","journal-title":"Br J Cancer"},{"issue":"13","key":"2808_CR47","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1200\/JCO.2006.08.1455","volume":"25","author":"JP Wisnivesky","year":"2007","unstructured":"Wisnivesky JP, Halm EA (2007) Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 25(13):1705\u20131712. https:\/\/doi.org\/10.1200\/JCO.2006.08.1455","journal-title":"J Clin Oncol"},{"issue":"18","key":"2808_CR48","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1128\/MCB.00280-13","volume":"33","author":"A Sugathan","year":"2013","unstructured":"Sugathan A, Waxman DJ (2013) Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol Cell Biol 33(18):3594\u20133610. https:\/\/doi.org\/10.1128\/MCB.00280-13","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2808_CR49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc.2016.30","volume":"16","author":"A Clocchiatti","year":"2016","unstructured":"Clocchiatti A, Cora E, Zhang Y et al (2016) Sexual dimorphism in cancer. Nat Rev Cancer 16(5):330\u2013339. https:\/\/doi.org\/10.1038\/nrc.2016.30","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2808_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nri2394","volume":"8","author":"EN Fish","year":"2008","unstructured":"Fish EN (2008) The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8(9):737\u2013744. https:\/\/doi.org\/10.1038\/nri2394","journal-title":"Nat Rev Immunol"},{"key":"2808_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2042-6410-3-3","volume":"3","author":"T Sun","year":"2012","unstructured":"Sun T, Warrington NM, Rubin JB (2012) Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. Biol Sex Differ 3:3. https:\/\/doi.org\/10.1186\/2042-6410-3-3","journal-title":"Biol Sex Differ"},{"key":"2808_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13293-020-00291-x","volume":"11","author":"JB Rubin","year":"2020","unstructured":"Rubin JB, Lagas JS, Broestl L et al (2020) Sex differences in cancer mechanisms. Biol Sex Differ 11:17. https:\/\/doi.org\/10.1186\/s13293-020-00291-x","journal-title":"Biol Sex Differ"},{"issue":"12","key":"2808_CR53","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1124\/dmd.110.035345","volume":"38","author":"CJ Gallagher","year":"2010","unstructured":"Gallagher CJ, Balliet RM, Sun D et al (2010) Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos 38(12):2204\u20132209. https:\/\/doi.org\/10.1124\/dmd.110.035345","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2808_CR54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1517\/17425255.4.4.413","volume":"4","author":"MJ Scandlyn","year":"2008","unstructured":"Scandlyn MJ, Stuart EC, Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Brug Metab Toxicol 4(4):413\u2013424. https:\/\/doi.org\/10.1517\/17425255.4.4.413","journal-title":"Expert Opin Brug Metab Toxicol"},{"key":"2808_CR55","doi-asserted-by":"publisher","first-page":"11762","DOI":"10.1038\/ncomms11762","volume":"7","author":"MK Ruhland","year":"2016","unstructured":"Ruhland MK, Loza AJ, Capietto A-H et al (2016) Stromal senescence establishes an immunosoppressive microenvironment that drives tumorigenesis. Nat Commun 7:11762. https:\/\/doi.org\/10.1038\/ncomms11762","journal-title":"Nat Commun"},{"issue":"1","key":"2808_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neo.2014.12.001","volume":"17","author":"K Kramer","year":"2015","unstructured":"Kramer K, Wolf S, Mayer B et al (2015) Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia 17(1):134\u2013140. https:\/\/doi.org\/10.1016\/j.neo.2014.12.001","journal-title":"Neoplasia"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02808-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:40:52Z","timestamp":1757184052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02808-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2808"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02808-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}